Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1148-1155

  Pentheroudakis, George ^a   Briasoulis, Evangelos ^a   Kalofonos, Haralambos P ^b   Fountzilas, Georgios ^c   Economopoulos, Theofanis ^d   Samelis, George ^e   Koutras, Aris ^b   Karina, Maria ^c   Xiros, Nikolaos ^d   Samantas, Epameinondas ^f   Bamias, Aristotelis ^g   Pavlidis, Nikolaos ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER TOXICITY; LYMPHADENOPATHY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREECE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; OUTPATIENTS; PALLIATIVE CARE; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 51149110316     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701843043     Document Type: Article

References (32)

1. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243-50.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990-2005.
3. Pentheroudakis G, Briasoulis E, Karavasilis V, Fountzilas G, Xeros N, Samelis G, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? Acta Oncol 2005;44:155-60.
4. Briasoulis E, Tsokos M, Fountzilas G, et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications: A Hellenic Cooperative Oncology Group study. Anticancer Res 1998;18:1907-14.
5. Konecny G. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumour samples. Breast Cancer Res Treat 2001;67:223-33.
6. Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-Carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy and safety. Med Oncol 2006;23:147-60.
7. Vasey PA. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 2003;21(Suppl 10):136s-44s.
8. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
9. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
11. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007;46:592-601.
13. Hainsworth J, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin and extended schedule etoposide. J Clin Oncol 1997;15:2385-93.
14. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II study. The Hellenic Cooperative Oncology Group study. J Clin Oncol 2000;18:3101-17.
15. Greco FA, Burris HA 3rd, Erland EB, Gray JR, Kalman LA, Schreeder MT, et al. Carcinoma of unknown primary site. Cancer 2000;89:2655-60.
16. Greco FA, Gray J, Burris HA, Erland JB, Morrissey LH, Hainsworth JD. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 2001;7:203-12.
17. Bouleuc C, Saghatchian M, Di Tullio L, Louvet Ch, Levy E, Di Palma M, et al. A multicentre phase II study of docetaxel and cisplatin in the treatment of cancer of unknown primary site. Proc Am Soc Clin Oncol 2001;137b:2298.
18. Gothelf A, Daugaard G, Nelausen K. Paclitaxel, cisplatin and gemcitabine in the treatment of unknown primary tumours, a phase II study. Proc ESMO 2002;25:88.
19. Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richard SP, et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20:1651-6.
20. Mukai H, Watanabe T, Ando M, Katsumata N. Unknown primary carcinoma: A feasibility assessment of combination chemotherapy with cisplatin and docetaxel. Int J Clin Oncol 2003;8:23-5.
21. Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, et al. Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan. A Minnie Pearl Cancer Research Network phase II trial. The Oncologist 2004;9:644-52.
22. Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 2004;34:681-5.
23. El-Rayes BF, Shields AF, Zalupski M, Heilbrum K, Jain V, Terry D, et al. A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 2005;28:152-6.
24. Hainsworth J, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network study. J Clin Oncol 2006;24:3548-54.
25. Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, et al. Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000;11:211-5.
26. Berry W, Elkordy M, O Rourke M, Khan M, Asmar L. Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: A reasonable regimen for the community-based clinic? Cancer Invest 2007;25:27-31.
27. Pouessel D, Culine S, Brecht C, Ychou M, Romieu G, Fabbro M, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004;100:1257-61.
28. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site. J Clin Oncol 2002;20:4679-83.
29. Pentheroudakis G, De Bono JS, Kaye SB, Simpson A, Paul J, Brown I, et al. Improved prognosis of patients with intermediate-and poor-risk non seminomatous germ cell tumours by optimising combined treatment. BJU Int 2003;92:36-42.
30. Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with poor prognosis metastatic non seminomatous germ cell tumours. J Natl Cancer Inst 1999;91:839-46.
31. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: Missing primary or missing biology? The Oncologist 2007;12:418-25.
32. Hainsworth J, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-52.